Incidence of postpartum haemorrhage in women receiving therapeutic doses of low-molecular-weight heparin: results of a retrospective cohort study

Sara Roshani, Danny M Cohn, Alexander C Stehouwer, Hans Wolf, Joris A M van der Post, Harry R Büller, Pieter W Kamphuisen, Saskia Middeldorp, Sara Roshani, Danny M Cohn, Alexander C Stehouwer, Hans Wolf, Joris A M van der Post, Harry R Büller, Pieter W Kamphuisen, Saskia Middeldorp

Abstract

Background Low-molecular-weight heparin (LMWH) is the drug of choice to prevent venous thrombosis in pregnancy, but the optimal dose for prevention while avoiding bleeding is unclear. This study investigated whether therapeutic doses of LMWH increase the incidence of postpartum haemorrhage (PPH) in a retrospective controlled cohort. Methods All pregnant women who received therapeutic doses of LMWH between 1995 and 2008 were identified in the Academic Medical Center, Amsterdam, The Netherlands. The controls were women registered for antenatal care in the same hospital who did not use LMWH during pregnancy, matched by random electronic selection for age, parity and delivery date to LMWH users. The incidence of PPH (blood loss >500 ml), severe PPH (blood loss >1000 ml) and median blood loss were compared in two cohorts of LMWH users and non-users. Results The incidence of PPH was 18% in LMWH users (N=95) and 22% in non-users (N=524) (RR 0.8; 95% CI 0.5 to 1.4). The incidence of severe PPH was 6% in both groups (RR 1.2; 0.5 to 2.9). The median amount of blood loss differed only in normal vaginal deliveries. It was 200 ml in LMWH users and 300 ml in non-users (difference -100 ml; 95% CI -156 to -44). Conclusion Therapeutic doses of LMWH in pregnancy were observed not to be associated with a clinically meaningful increase in the incidence of PPH or severe PPH in women delivered in this hospital, although this observation may be confounded by the differential use of strategies to prevent bleeding. A randomised controlled trial is necessary to provide a definite answer about the optimal dose of LMWH in pregnancy.

Conflict of interest statement

Competing interests: None.

Figures

Figure 1
Figure 1
Inclusion flowchart of women treated with low-molecular-weight heparin.

References

    1. Bates SM, Greer IA, Pabinger I, et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:844S–86S
    1. World Health Organization Managing complications in pregnancy and childbirth: a guide for midwives and doctors. Integrated Management of Pregnancy and Childbirth 2003
    1. Kominiarek MA, Angelopoulos SM, Shapiro NL, et al. Low-molecular-weight heparin in pregnancy: peripartum bleeding complications. J Perinatol 2007;27:329–34
    1. Bais JM, Eskes M, Pel M, et al. Postpartum haemorrhage in nulliparous women: incidence and risk factors in low and high risk women. A Dutch population-based cohort study on standard (> or = 500 ml) and severe (> or = 1000 ml) postpartum haemorrhage. Eur J Obstet Gynecol Reprod Biol 2004;115:166–72
    1. Dildy GA., III Postpartum hemorrhage: new management options. Clin Obstet Gynecol 2002;45:330–44
    1. Royal College of Obstetricians and Gynaecologists Thromboembolic disease in pregnancy and the puerperium: acute management. Guideline No 28. London, UK: Royal College of Obstetricians and Gynaecologists, 2007
    1. Dulitzki M, Pauzner R, Langevitz P, et al. Low-molecular-weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies. Obstet Gynecol 1996;87:380–3
    1. Maslovitz S, Many A, Landsberg JA, et al. The safety of low molecular weight heparin therapy during labor. J Matern Fetal Neonatal Med 2005;17:39–43
    1. Rowan JA, McLintock C, Taylor RS, et al. Prophylactic and therapeutic enoxaparin during pregnancy: indications, outcomes and monitoring. Aust NZ J Obstet Gynaecol 2003;43:123–8
    1. Nelson-Piercy C, Letsky EA, De Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol 1997;176:1062–8
    1. Voke J, Keidan J, Pavord S, et al. The management of antenatal venous thromboembolism in the UK and Ireland: a prospective multicentre observational survey. Br J Haematol 2007;139:545–58
    1. Bauersachs RM, Dudenhausen J, Faridi A, et al. Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women. Thromb Haemost 2007;98:1237–45
    1. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005;106:401–7
    1. Sanson BJ, Lensing AW, Prins MH, et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999;81:668–72
    1. Lepercq J, Conard J, Borel-Derlon A, et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. BJOG 2001;108:1134–40
    1. Roeters van Lennep JE, Meijer E, Klumper FJ, et al. Prophylaxis with low-dose low-molecular-weight heparin during pregnancy and postpartum: is it effective? J Thromb Haemost 2011;9:473–80
    1. Begley CM. A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery 1990;6:3–17
    1. Khan GQ, John IS, Wani S, et al. Controlled cord traction versus minimal intervention techniques in delivery of the placenta: a randomized controlled trial. Am J Obstet Gynecol 1997;177:770–4
    1. Rogers J, Wood J, McCandlish R, et al. Active versus expectant management of third stage of labour: the Hinchingbrooke randomised controlled trial. Lancet 1998;351:693–9
    1. Nordstrom L, Fogelstam K, Fridman G, et al. Routine oxytocin in the third stage of labour: a placebo controlled randomised trial. Br J Obstet Gynaecol 1997;104:781–6
    1. van Wijk FH, Wolf H, Piek JM, et al. Administration of low molecular weight heparin within two hours before caesarean section increases the risk of wound haematoma. Br J Obstet Gynaecol 2002;109:955–7
    1. Larsson C, Saltvedt S, Wiklund I, et al. Estimation of blood loss after cesarean section and vaginal delivery has low validity with a tendency to exaggeration. Acta Obstet Gynecol Scand 2006;85:1448–52

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir